EarningsQ1 2026 Earnings Report
DE:87S Q1 2026 EPS Results
Actual EPS-€0.30
Consensus EPS-€0.27
Beat/MissMissed by -€0.03
One Year Ago EPS-€0.22
DE:87S Q1 2026 Revenue Results
Actual Revenue€1.29M
Expected Revenue€1.84M
Beat/MissMissed by -€548.83K
YoY Revenue Growth-33.55%
Earnings Announcement Details
QuarterQ1 2026
Date08/06/2026
TimeBefore Open
Conference CallThursday, August 6, 2026
DE:87S Upcoming Earnings
Roivant Sciences's next earnings date is estimated for November 9, 2026, based on past reporting schedules.
Q1 2026 Earnings Call Audio
DE:87S Q1 2026 Earnings Call
0:00 / 0:00
Q1 2026 Earnings Slide Deck
Q1 2026 Earnings Call Summary
Earnings Call Sentiment|Positive
The call emphasized strong pipeline progress (potential DM launch, Phase III initiation in cutaneous sarcoidosis, multiple H2 2026 readouts), a sizable settlement cash inflow, active share buybacks, and continued R&D investment. Management was candid about clinical and regulatory risks (placebo variability, translation risk for PH‑ILD, randomized withdrawal uncertainty in D2T RA), limited early commercial visibility, JAK class safety perceptions, and contingent litigation outcomes. On balance, the positives (multiple near-term catalysts, strengthened balance sheet, active capital return, and robust R&D investment) outweigh the enumerated risks, which are largely development and execution uncertainties the company is actively managing.Company Guidance
Potential Near-Term Launch of Brepocitinib in Dermatomyositis (DM)
Priority review and a PDUFA this quarter with a potential launch by end of September; commercial and patient-support teams built and ready; company guiding a "slow and steady" launch strategy to lay groundwork across multiple indications.
Phase III Cutaneous Sarcoidosis (CS) Initiated — Strong Phase II Efficacy
Phase III enrollment begun (140 patients across ~70 sites; 3:2 randomization = ~60% active / 40% placebo) with primary endpoint CSAMI >=50% response at 16 weeks; Phase II showed >20-point CSAMI benefit vs roughly no change on placebo and treatment arm rates well north of a 50% CSAMI >=50% response while placebo was near 0.
Additional Registrational Programs Progressing (LPP, NIU, CLE, PH‑ILD)
Lichen planopilaris (LPP) study enrolling extremely well; NIU top-line data expected in H2 2026; CLE POC primary 12-week readout in H2 2026; mosli (PH‑ILD) Phase II top-line expected in H2 2026 — broad pipeline catalyst calendar with many pivotal readouts ahead.
Significant Settlement Cash Inflow and Balance Sheet Strength
Received $950 million upfront in the Moderna settlement (approximately $770–772M to Genevant and remainder to Arbutus); cash reported just under $4.0 billion before receipt of the ~$772M tranche, strengthening liquidity ahead of upcoming catalysts.
Active Capital Return via Share Repurchases
Accelerated share repurchases with ~ $200 million repurchased in the quarter (and prior buybacks totaling roughly $1.5 billion through mid last year); recent repurchases averaged in the high-$20s vs prior ~$10 average in the first round, indicating opportunistic capital return.
Continued Investment in R&D and Operations
Quarterly R&D expense approximately $200 million; GAAP G&A ~$166 million and non‑GAAP adjusted G&A just under $100 million — shows active investment behind multiple clinical programs.
Rich Near- and Mid-Term Catalyst Roadmap
Company expects a busy period: NIU, PH‑ILD, CLE readouts in H2 2026, further D2T RA updates and FDA discussion in H2, Graves pivotal readout and additional launches into 2027 and a plan for 3+ commercial launches, 9+ pivotal readouts and 4+ NDA/BLAs by end of 2028.
DE:87S Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed